ClinicalTrials.gg
CompletedNCT03548311JETALSUpdated Mar 26, 2025

Clinical Trial of Ultra-high Dose Methylcobalamin for ALS

A Phase 3 interventional study of methylcobalamin and saline solution in Amyotrophic Lateral Sclerosis, sponsored by Eisai Co., Ltd.. Completed at 16 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Eisai Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2017, registered May 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan — 2 open to participants now, 4 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Japan.

Enrollment
12th of 20
130 · median 136
Started
2017
with 1 other
Phase 3
8 of 21
none open now
Registered
9th of 21
by date
Lead sponsor
3 of 21
Eisai Co., Ltd.

Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, this one is the 12th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2017, is one of 8 in phase 3, and was the 9th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

2 of the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, or all of them as a file.
02

Study summary

To examine the clinical efficacy and safety of ultra-high dose (50mg, im, twice a week) methylcobalamin in retarding the progression of symptoms in amyotrophic lateral sclerosis (ALS) patients, we enroll ALS patients diagnosed by Updated Awaji Criteria within 12 months after the clinical onset. First they are followed for 12 weeks with Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) scores, and only those who exhibit drops of 1-2 points are allowed to enter into the test period. A total of 128 patients are randomized and the half having placebo. They are blindly evaluated for drops of ALSFRS-R in 16 weeks, as the primary outcome. After this, all subjects receive methylcobalamin.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS
  • motor neuron disease
  • Lou Gehrig's disease
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Treatment and OLE Phase:

  • ALS patients within 12 months after clinical onset at the entry
  • Diagnosed based on updated Awaji criteria: definite, probably or laboratory supported probable
  • Decline of ALSFRSR being 1 or 2 during observation period of 12 weeks
  • Japanese Clinical Severity Scale 1 or 2
  • Those who can visit the participating medical centers

Tsunagi Phase:

  • The subjects for the Tsunagi phase are patients with ALS who are continuing the administration of this drug at the time of approval, and have obtained consent for the transition to the Tsunagi phase.

Exclusion criteria

Exclusion Criteria:

Treatment and OLE Phase:

  • Those who have tracheostomy
  • Those who had NIPPV
  • %FVC\<60%
  • Those who have (COPD)
  • Those who have symptoms and signs of B12 deficiency
  • Those who had edaravone less than 4 weeks prior to entry
  • Those who changed the schedule and dosing of riluzole
  • Those who have dementia
  • Those who have the possibility of pregnancy
  • Those who have serious respiratory or cardiac diseases
  • Those who have
  • Those who participated other clinical trials within 12 weeks
  • Those who have allergies to B12 and related compounds

Tsunagi Phase:

Not applicable.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (actual)

Study arms

  • Placebo comparator
    Treatment Phase: Placebo

    intramuscular injection of saline solution

    Drug: saline solution

  • Active comparator
    Treatment Phase: methylcobalamin

    intramuscular injection of methylcobalamin

    Drug: methylcobalamin

  • Experimental
    OLE Phase: methylcobalamin

    intramuscular injection of methylcobalamin

    Drug: methylcobalamin

  • Experimental
    Tsunagi Phase: methylcobalamin

    intramuscular injection of methylcobalamin

    Drug: methylcobalamin

Interventions

  • Patients receive methylcobalamin 50mg intramuscular injection twice a week.

  • Drugsaline solution

    Patients receive saline solution intramuscular injection twice a week.

06

What researchers measure

Primary outcomes

  1. Treatment Phase: ALSFRS-R

    Drop of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (maximum or normal 48 and minimum 0; higher values represent better condition)

    Time frame: during 16 weeks of test period

Secondary outcomes

  1. Treatment Phase: time to event

    time from the randomization to the onset of any of the event (24-hour use of noninvasive respiratory support, use of invasive respiratory support, or death)

    Time frame: during 16 weeks of test period

  2. Treatment Phase: %Functional Vital Capacity (FVC)

    changes of per cent Functional Vital Capacity

    Time frame: during 16 weeks of test period

  3. Treatment Phase: homocystein

    changes of serum levels of homocystein

    Time frame: during 16 weeks of test period

  4. Treatment Phase: Manual Muscle Testing (MMT)

    changes of sum of Medical Research Council scales of manual muscle testing, ranging 5 (normal), 4, 4+, 3, 2, 1, 0 (minimal) ( for analysis each is converted to 6, 5, 4, 3, 2, 1, 0) of the 11 muscles in the limbs (5x2) and neck(1)

    Time frame: during 16 weeks of test period

  5. Treatment Phase: Norris scale

    changes of Norris scale (39 normal - 0 worst)

    Time frame: during 16 weeks of test period

  6. Treatment Phase: Grip Power

    changes of sum of grip power in kilograms on both sides

    Time frame: during 16 weeks of test period

  7. Treatment Phase: 40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40)

    changes of sum of ALSAQ-40 (40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire) score (40 normal - 200 worst)

    Time frame: during 16 weeks of test period

Other outcomes

  1. Treatment Phase: safety

    any adverse events during the treatment period

    Time frame: during 16 weeks of test period

  2. OLE Phase: time to event

    time from the randomization to the onset of any of the event (24-hour use of noninvasive respiratory support, use of invasive respiratory support, or death)

    Time frame: up to 6 years 11 months

  3. OLE Phase: ALSFRS-R

    Drop of ALSFRS-R Scale-Revised (maximum or normal 48 and minimum 0; higher values represent better condition)

    Time frame: up to 6 years 11 months

  4. OLE Phase: safety

    any adverse events during the OLE period including laboratory tests and vital signs assessment.

    Time frame: up to 6 years 11 months

  5. Tsunagi Phase: time to event

    time period from drug assignment to any of the event (24-hour use of noninvasive respiratory support, use of invasive respiratory support, or death)

    Time frame: up to 6 months

  6. Tsunagi Phase: ALSFRS-R

    Drop of ALSFRS-R Scale-Revised (maximum or normal 48 and minimum 0; higher values represent better condition)

    Time frame: up to 6 months

  7. Tsunagi Phase: safety

    any adverse events during the Tsunagi phase including laboratory tests and vital signs assessment.

    Time frame: up to 6 months

07

Study locations

16 sites
  • Nagoya University Hospital
    Nagoya, Aichi 466-8560, Japan
  • Miyoshi Neurological Clinic
    Miyoshi, Hiroshima 728-0013, Japan
  • Sapporo Medical University Hospital
    Sapporo, Hokkaido 060-8543, Japan
  • Kobe Central Munincipal Medical center
    Kobe, Hyogo 650-0047, Japan
  • Ioh National Hospital
    Kanazawa, Ishikawa 920-0192, Japan
  • Kitasato University East Hospital
    Sagamihara, Kanagawa 252-0380, Japan
  • Shiga Medical University Hospital
    Otsu, Shiga 520-2192, Japan
  • Chiba University Hospital
    Chiba, 260-8677, Japan
  • Murakami Karindo Hospital
    Fukuoka, 819-8585, Japan
  • Okayama University Hospital
    Okayama, 770-8558, Japan
  • Tokushima University Hospital
    Tokushima, 770-8503, Japan
  • Juntendo University Hospital
    Tokyo, 113-8431, Japan
  • Toho University Hospital
    Tokyo, 143-8541, Japan
  • Teikyo University Hospital
    Tokyo, 173-8606, Japan
  • Tokyo Metropolitan Neurological Hospital
    Tokyo, 183-0042, Japan
  • Wakayama Medical University Hospital
    Wakayama, 641-8509, Japan
08

References and documents

Publications

  • Ikeda K, Iwasaki Y, Kaji R. Neuroprotective effect of ultra-high dose methylcobalamin in wobbler mouse model of amyotrophic lateral sclerosis. J Neurol Sci. 2015 Jul 15;354(1-2):70-4. doi: 10.1016/j.jns.2015.04.052. Epub 2015 May 8. PubMed 25982504 ↗
  • Kaji R, Kodama M, Imamura A, Hashida T, Kohara N, Ishizu M, Inui K, Kimura J. Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Muscle Nerve. 1998 Dec;21(12):1775-8. doi: 10.1002/(sici)1097-4598(199812)21:123.0.co;2-v. PubMed 9843082 ↗
  • Oki R, Izumi Y, Fujita K, Miyamoto R, Nodera H, Sato Y, Sakaguchi S, Nokihara H, Kanai K, Tsunemi T, Hattori N, Hatanaka Y, Sonoo M, Atsuta N, Sobue G, Shimizu T, Shibuya K, Ikeda K, Kano O, Nishinaka K, Kojima Y, Oda M, Komai K, Kikuchi H, Kohara N, Urushitani M, Nakayama Y, Ito H, Nagai M, Nishiyama K, Kuzume D, Shimohama S, Shimohata T, Abe K, Ishihara T, Onodera O, Isose S, Araki N, Morita M, Noda K, Toda T, Maruyama H, Furuya H, Teramukai S, Kagimura T, Noma K, Yanagawa H, Kuwabara S, Kaji R; Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) Collaborators. Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2022 Jun 1;79(6):575-583. doi: 10.1001/jamaneurol.2022.0901. PubMed 35532908 ↗
  • Oki R, Izumi Y, Nodera H, Sato Y, Nokihara H, Kanai K, Sonoo M, Urushitani M, Nishinaka K, Atsuta N, Kohara N, Shimizu T, Kikuchi H, Oda M, Ikeda K, Nagai M, Komai K, Kojima Y, Kuzume D, Isose S, Shimohama S, Abe K, Ito H, Noda K, Ishihara T, Morita M, Shimohata T, Teramukai S, Kagimura T, Noma K, Yanagawa H, Kuwabara S, Kaji R; JETALS. The Japanese Early-Stage Trial of High-Dose Methylcobalamin for Amyotrophic Lateral Sclerosis (JETALS): Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2018 Dec 21;7(12):e12046. doi: 10.2196/12046. PubMed 30578206 ↗

Individual participant data

Plan to share: Yes — anonymous data are available

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: from October 1, 2017 till March 31, 2020

Access criteria: those who have approval from Institutional Review Board (IRB)

Data sharing details ↗ · als-mecobalamin.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Feb 2020, 27 months.

Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 27 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2018
First posted
Jun 7, 2018
StartActual
Nov 1, 2017
Primary completionActual
Feb 14, 2020
CompletionActual
Feb 18, 2025
Last update
Mar 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03548311
Lead sponsor
Eisai Co., Ltd.
Collaborators
University of Tokushima
Responsible party
Sponsor
First posted
Jun 7, 2018
Start date
Nov 1, 2017
Primary completion
Feb 14, 2020
Completion
Feb 18, 2025
Last update
Mar 26, 2025

Study contacts

Ryuji Kaji, MD
study director · Tokushima University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mecobalamin

Start the discussion